The present invention relates to an ophthalmic pharmaceutical composition comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent along with a complexing agent and water. The composition is having a pH between 4 and 8. The present invention also relates to the methods of making an ophthalmic pharmaceutical composition and there uses thereof. The present invention also provides a method of treating and/or preventing an ophthalmic condition in a patient.

The present invention relates to an ophthalmic pharmaceutical composition comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent along with a complexing agent and water. The composition is having a pH between 4 and 8. The present invention also relates to the methods of making an ophthalmic pharmaceutical composition and there uses thereof. The present invention also provides a method of treating and/or preventing an ophthalmic condition in a patient.

The present disclosure relates to methods for treating Thyroid Eye Disease (e.g., Graves' Orbitopathy) using Interleukin (IL)-17 antagonists, e.g., secukinumab. Also disclosed herein are IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating patients having Thyroid Eye Disease (e.g., Graves' Orbitopathy), as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

The present invention provides a method for treating an ocular disease or condition in a subject, comprising administering to the subject’s ocular tissue a composition comprising an effective amount of one or more bioactive agents, wherein the composition is administered with a single-chamber or multi-chamber microchannel delivery device.

Disclosed are an IL-5 binding molecule, and a preparation method and use thereof. The binding molecule includes the following complementarity determining regions: an amino acid sequence of CDR1 selected from any one of sequences as set forth in SEQ ID NOs. 43-49; an amino acid sequence of CDR2 selected from any one of sequences as set forth in SEQ ID NOs. 50-56; and an amino acid sequence of CDR3 selected from any one of sequences as set forth in SEQ ID NOs. 57-62. The binding molecule is capable of specifically binding to IL-5, and effectively blocking the cell proliferation induced by IL-5.

Nucleic acid constructs and compositions that allow insertion and/or expression of a retinoschisin coding sequence are provided. Nuclease agents targeting RS1 loci are provided. Compositions and methods of using such constructs for integration into a target genomic locus and/or expression in a cell are also provided. Methods of treating X-linked juvenile retinoschisis using the nucleic acid constructs and compositions are also provided.

Nucleic acid constructs and compositions that allow insertion and/or expression of a retinoschisin coding sequence are provided. Nuclease agents targeting RS1 loci are provided. Compositions and methods of using such constructs for integration into a target genomic locus and/or expression in a cell are also provided. Methods of treating X-linked juvenile retinoschisis using the nucleic acid constructs and compositions are also provided.

Compositions, systems and methods for delivering CRISPR/Cas9-based genome editing system and a donor protein to a cell.

Compositions, systems and methods for delivering CRISPR/Cas9-based genome editing system and a donor protein to a cell.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,

##STR00001##

wherein

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and G are defined as in claim 1,

and prodrugs or pharmaceutically acceptable salts of these compounds

for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).